Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
about
Chemoresistance and targeted therapies in ovarian and endometrial cancersFulvestrant for the treatment of endometrial cancer.Lipocalin 2 Enhances Migration and Resistance against Cisplatin in Endometrial Carcinoma Cells.Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowAnalysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyRecent Advances in Endometrial Cancer.A Review of mTOR Pathway Inhibitors in Gynecologic CancerComprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options.Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Emerging drugs for endometrial cancer.Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsEndometrial Carcinoma: Specific Targeted Pathways.Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.New therapies for advanced, recurrent, and metastatic endometrial cancers.Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
P2860
Q28073246-145AA594-4C21-4DFE-AEE5-B8785E4C4DE0Q34514391-87262931-0D6E-4B96-98FB-DE057672FF6DQ36014604-BAFBC34B-94B6-4EAF-BA2B-070F8F2A2E79Q36418630-99F8EEA3-CF55-4C65-9CCF-E3C43E1FB729Q36731185-776C6CBD-16F4-4A81-86D7-241FD7316D85Q36804506-8B4D07C0-14C6-408C-A189-68CEE3FCB9ADQ37429034-59CE73D4-D7FE-44A6-9D9F-7B5EEFCCFE9DQ37620470-7CAA6F2A-D347-4E9B-BFE1-B1DCD992E35DQ37668889-772BE923-6900-4839-9060-E1985F46654AQ37710456-117AE358-7311-4D9E-A120-C14B35CFD87EQ38203354-560B3272-D32C-4045-A929-C6952C65E4B5Q38242086-D453DA97-875F-41D2-970B-D93D6D0EBD6AQ38261469-7671508E-FAC9-4359-9827-8841F75FBC8FQ38631272-2FB2F1CD-0F7E-4144-8427-2366292030FCQ38753038-EF828FBE-4D73-401B-A0BB-FB265A142868Q38895754-ACAD3F72-37AF-4073-A7AF-6DA4074F2239Q39026766-92E7EDE5-E347-4C8D-A804-FD0A19C54194Q45848384-8DB8F1DF-816E-4322-8DC2-C8434F68CF7BQ46909057-34944A0C-6ABD-47A7-8A75-80F3C0952882Q47103210-F30A2E87-4EDC-4185-8F6D-CFA39E5BD356Q55005815-3857C67D-5BA9-44F3-B813-D7265961BB03
P2860
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Everolimus as second- or third ...... D, a phase II trial of GINECO.
@en
type
label
Everolimus as second- or third ...... D, a phase II trial of GINECO.
@en
prefLabel
Everolimus as second- or third ...... D, a phase II trial of GINECO.
@en
P2093
P2860
P356
P1476
Everolimus as second- or third ...... D, a phase II trial of GINECO.
@en
P2093
A Plantade
C Roemer-Becuwe
E Pujade-Lauraine
P2860
P2888
P304
P356
10.1038/BJC.2013.183
P407
P577
2013-04-23T00:00:00Z